Lab Prior Authorization

Similar documents
The Prior Authorization List 2017

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012

Original Policy Date

General Approach to Genetic Testing

General Approach to Evaluating the Utility of Genetic Panels. Policy Specific Section: Medical Necessity and Investigational / Experimental

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Necessity Guidelines: Genetic and Molecular Diagnostic Testing

General Approach to Evaluating the Utility of Genetic Panels

Centers for Medicare and Medicaid Services

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Genetic Testing for Inherited Conditions

The Prior Authorization List

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

OHCA Molecular Pathology Overview

Genetic Testing for Lynch Syndrome

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Prior Authorization. Additional Information:

Calendar Year (CY) 2016 Clinical Laboratory Fee Schedule (CLFS) Preliminary Determinations

PROVIDER POLICIES & PROCEDURES

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

Code CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis

Codes for inclusion in the Laboratory Benefit Management Program

MEDICAL POLICY No R12 GENETICS: COUNSELING, TESTING, SCREENING

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

OHCA Molecular Pathology Overview

Molecular Diagnostic Testing Prior Authorization

Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology

American Imaging Management, Inc.

JOHNS HOPKINS HEALTHCARE. Medical Policy: Genetic Testing Department: Health Services Lines of Business: EHP, USFHP, PPMCO, ADVANTAGE MD

MOLECULAR PATHOLOGY/MOLECULAR DIAGNOSTICS/ GENETIC TESTING

Calendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations

NEW YORK STATE MEDICAID PROGRAM LABORATORY PROCEDURE CODES

NutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Prior Authorization Required: Additional Information:

CPT 2016 Code Changes

ACMG/CAP Cytogenetics CY

Prior Authorization. Additional Information:

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

CHRONIC MYELOGENOUS LEUKEMIA

CPT Codes for Pharmacogenomic Tests

HHA Medical Products and Services Requiring Preauthorization

Medical Policy Update

Diagnostics for the early detection and prevention of colon cancer

CLINICAL MEDICAL POLICY

Out-Patient Billing CPT Codes

General Approach to Genetic Testing

Medical Products and Services Requiring Notification or Preauthorization

Re: NC Medicaid and NC Health Choice Program coverage of genetic testing for susceptibility to breast and ovarian cancer

PA Orthotics & Prosthetics with billed amount exceeding $15,0000. PA 55 Place of Service Residential Substance Abuse Treatment Facility

NEW YORK STATE MEDICAID PROGRAM LABORATORY PROCEDURE CODES

August 17, Dear Valued Client:

The following codes are under management for members who have health benefits covered by WellCare, administered by evicore healthcare.

Medical Products and Services Requiring Notification or Preauthorization

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Blue Cross Blue Shield of Arizona

CANCER GENETICS PROVIDER SURVEY

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

Anatomic Molecular Pathology: An Emerging Field

oncogenes-and- tumour-suppressor-genes)

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Information for You and Your Family

Contractor Information. LCD Information

Development of Carcinoma Pathways

LIST OF INVESTIGATIONS

Medical Policy. Description/Scope. Position Statement

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

HEREDITY & CANCER: Breast cancer as a model

Multistep nature of cancer development. Cancer genes

Genetic Testing for Neurologic Disorders

Corporate Medical Policy

Account # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5

Determination Differentiation. determinated precursor specialized cell

Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

The Next Generation of Hereditary Cancer Testing

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION

Genomics and Genetics in Healthcare. By Mary Knutson, RN, MSN

Genetic Diseases. SCPA202: Basic Pathology

Cancer genetics

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

Genetic Testing for Somatic Tumor Markers

CLINICAL MEDICAL POLICY

Genetic Testing for BRCA1 and BRCA2 Genes

Molecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras

CLINICAL MEDICAL POLICY

Genetic Testing for Single-Gene and Multifactorial Conditions

molecular oncology services

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007

Subject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)

Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17

Colon Cancer and Hereditary Cancer Syndromes

Transcription:

Lab Prior Authorization On July 22, 2015, BlueCross BlueShield of South Carolina announced that it will partner with Avalon Healthcare Solutions (Avalon) to administer a comprehensive suite of laboratory benefits management services to promote patients access to affordable, high quality health care. Effective January 1, 2016, BlueCross will require Avalon to precertify certain lab procedures when performed in an office, outpatient or independent lab location. Avalon is an independent company that provides benefit management services on behalf of BlueCross. Avalon relies on evidenced-based, clinically validated medical literature, published national health care guidelines, promulgated clinical protocols, the scientific and clinical expertise of its Clinical Advisory Board, and other resources as deemed appropriate by Avalon to develop its medical policies. These policies, further approved by client health plans, provide the foundation for medical necessity decisionmaking that promotes a member s receipt of the right laboratory test at the right time and place. Avalon has developed the following matrix in an effort to help you determine when you need to contact Avalon for prior authorization. This matrix is designed to assist you in submitting the appropriate code(s) to obtain the diagnostic information you require for your patient s treatment plan. You may submit requests for prior authorization by fax or phone. Avalon will promptly review your request for medical necessity and provide you with a timely, written decision. *Please note: Services rendered in an Emergency Room, Observation Room, Surgery Center or Hospital Inpatient Setting are not managed by Avalon. This document is current as of the date posted and is subject to change. Payment is subject to plan coverage and benefits at the time of service. CPT Code BCR-ABL 1 Testing for Chronic Myeloid Leukemia 81206 BCR/ABL1 (t(9:22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative 81207 Minor breakpoint, qualitative or quantitative 81208 Other breakpoint, qualitative or quantitative 81401 Molecular pathology procedure, Level 2 88271-75 88271: Molecular cytogenetics; DNA probe, each (eg, FISH) 88272: Chromosomal in situ hybridization, analyze 3-5 cells (eg. for derivatives and markers) 88273: Chromosomal in situ hybridization, analyze 10-30 cells 88274: interphase in situ hybridization, analyze 25-99 cells 88275: interphase in situ hybridization, analyze 100-300 cells BRCA 81211 BRCA1, BRCA2 gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1 kb) 81212 185delAG, 5385insC, 6174delT variants 81213 Uncommon duplication/deletion variants (BRCA1, BRCA2 ) 81214 BRCA1 (breast cancer 1 eg: hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie: exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) 81215 known familial variant 81216 BRCA2 gene analysis, full sequence analysis (*Note: when performing BRCA2 full sequence analysis with BRCA1 full sequence analysis, procedure code 81211 should be used) 81217 Known familial variant 88271-88275 Molecular cytogenics

81228 Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chormosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis 81229 Interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities S3870 Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or mental retardation Cytochrome P450 Genetic Testing 81225 CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, 81226 CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis 81235 EGFR (epidermal growth factor receptor) (eg, mom-small cell lung gancer) gene analysis 81201 APC 9 (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence 81202 Known familial variants 81203 duplication/deletion variants 81401 Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication /deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia when specified as the following: MUTYH (muty homolog [E.coli]) (eg, MYH-associated polyposis), full gene sequence Flow Cytometry 88185 Each additional marker (listed separately in addition to code 88184 for the first marker). NOTE: PA required only if greater than 29 units are ordered. FLT3 and NPM1 Mutation in Acute Myeloid Leukemia 81245 FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; evaluation to detect abnormal (eg, expanded alleles) 81161-81479 Molecular pathology code range 81500-81599 MAAA tests (NOTE: Codes 81508-81512 NOT COVERED) 88230-88299 Cytogenetic studies code range S3800 Genetic testing for amyotrophic lateral sclerosis (ALS) S3841 S3842 S3844 S3845 S3846 S3849 S3850 S3853 Genetic testing for retinoblastoma Genetic testing for Von Hippel-Lindau disease DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness Genetic testing for alpha thalassemia Genetic testing for hemoglobin E beta-thalassemia Genetic testing for Niemann-Pick disease Genetic testing for sickle cell anemia Genetic testing for muscular dystrophy General Genetic Testing for Cardiac Ion Channelopathies 81280 Long QT syndrome gene analyses; full sequence analysis 81282 duplication/deletion variants 81403 KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2), full gene sequence 81405 CASQ2 [calsequestrin 2 (cardiac muscle)], full gene sequence 81407 Molecular pathology procedure, Level 8 81408 RYR2 (ryanodine receptor 2 (cardiac)), full gene sequence or targeted sequence analysis of > 50 exons S3861 Genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome 81222 Duplication/deletion variants 81223 Full gene sequence 81224 Intron 8 poly-t analysis (eg, male infertility) Chromosomal Microarray Epidermal Growth Factor Receptor (EGFR) Mutation Analysis for Patients with Non-Small Cell Lung Cancer (NSCLC) Familial Adenomatous Polyposis and MUTYH-Associated Polyposis General Genetic Testing Genetic Testing for Cystic Fibrosis Genetic Testing for Duchenne and Becker Muscular Dystrophy 81408 Molecular pathology Level 9, including DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy), full gene sequence

81228 Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chormosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis 81229 Interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities S3870 Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or mental retardation Cytochrome P450 Genetic Testing 81225 CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, 81226 CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis 81235 EGFR (epidermal growth factor receptor) (eg, mom-small cell lung gancer) gene analysis 81201 APC 9 (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence 81202 Known familial variants 81203 duplication/deletion variants 81401 Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication /deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia when specified as the following: MUTYH (muty homolog [E.coli]) (eg, MYH-associated polyposis), full gene sequence Flow Cytometry 88185 Each additional marker (listed separately in addition to code 88184 for the first marker). NOTE: PA required only if greater than 29 units are ordered. FLT3 and NPM1 Mutation in Acute Myeloid Leukemia 81245 FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; evaluation to detect abnormal (eg, expanded alleles) 81161-81479 Molecular pathology code range 81500-81599 MAAA tests (NOTE: Codes 81508-81512 NOT COVERED) 88230-88299 Cytogenetic studies code range S3800 Genetic testing for amyotrophic lateral sclerosis (ALS) S3841 S3842 S3844 S3845 S3846 S3849 S3850 S3853 Genetic testing for retinoblastoma Genetic testing for Von Hippel-Lindau disease DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness Genetic testing for alpha thalassemia Genetic testing for hemoglobin E beta-thalassemia Genetic testing for Niemann-Pick disease Genetic testing for sickle cell anemia Genetic testing for muscular dystrophy General Genetic Testing for Cardiac Ion Channelopathies 81280 Long QT syndrome gene analyses; full sequence analysis 81282 duplication/deletion variants 81403 KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2), full gene sequence 81405 CASQ2 [calsequestrin 2 (cardiac muscle)], full gene sequence 81407 Molecular pathology procedure, Level 8 81408 RYR2 (ryanodine receptor 2 (cardiac)), full gene sequence or targeted sequence analysis of > 50 exons S3861 Genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome 81222 Duplication/deletion variants 81223 Full gene sequence 81224 Intron 8 poly-t analysis (eg, male infertility) Chromosomal Microarray Epidermal Growth Factor Receptor (EGFR) Mutation Analysis for Patients with Non-Small Cell Lung Cancer (NSCLC) Familial Adenomatous Polyposis and MUTYH-Associated Polyposis General Genetic Testing Genetic Testing for Cystic Fibrosis Genetic Testing for Duchenne and Becker Muscular Dystrophy 81408 Molecular pathology Level 9, including DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy), full gene sequence

81242 FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis 81243 FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (expanded) alleles 81244 FMR1 (Fragile X mental retardation 1) gene analysis; characterization of alleles (e.g., expanded size and methylation status) 81404 Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis 81405 Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis Genetic Testing for PTEN Hamartoma Tumor Syndrome 81321 PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis 81322 Known familial variant 81323 Duplication/deletion variant Genetic Testing for RET Proto-oncogene in Medullary Carcinoma of the Thyroid 81302 MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis 81303 Known familial variant 81304 Duplication/deletion variant 81404 Molecular pathology procedure, Level 4 87901 HIV-1 reverse transcriptase and protease regions 87903 Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV1; first through 10 drugs tested 87904 each additional drug tested (list separately in addition to code for primary procedure) 87906 HIV-1 other region (eg.: integrase, fusion) 81270 JAK2 ( Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.val617phe (V617F) variant 81402 Molecular pathology procedure, Level 3 81210 BRAF (v-raf murine sarcomaviral oncogenehomolog B1) (eg, colon cancer), gene analysis; full sequence 81275 KRAS (v-ki-ras2 Kirsten rat sarcoma viral oncogene) (eg, carcinoma) gene analysis, variants in codon 12 and 13 81405 Molecular pathology procedure, Level 6 88363 Examination and selection of retrieval archival (ie.: previously diagnosed) tissue(s) for molecular analysis G0464 Cancer screening; stool-based dna and fecal occult hemoglobin (e.g., kras, ndrg4 and bmp3) 81210 BRAF (v-raf murine sarcoma viral oncogene homolog B1) (eg, colon cancer), gene analysis, V600E variant. 81288 Prometer methylation analysis for MLH1 gene analysis testing (mutl homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) 81292-81294 MLH1 genetic testing code range 81295-81297 MSH2 genetic testing code range Genetic Testing for Fanconi Anemia Genetic Testing for FMR1 Mutations Genetic Testing for Li-Fraumeni Syndrome Genetic Testing for Rett Syndrome HIV Genotyping and Phenotyping JAK2 and MPL Mutation Analysis in Myeloproliferative Neoplasms KRAS and BRAF Mutation Analysis in Colorectal Cancer Lynch Syndrome 81298-81300 MSH6 genetic testing code range Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair 81301 deficiency includes comparison of neoplastic and normal tissue, if performed 81317 - PMS2 Genetic Testing (postmeiotic segregation increased 2 81317-81319 81318 - known familial variants 81319 - duplication/deletion variants Non-invasive Prenatal Screening for Aneuploidy 81420 Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21 81507 Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy 0009M Fetal aneuploidy trisom risk

81200 ASPA (aspartoacylase)(eg, Canavan disease) gene analysis 81205 BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease) gene analysis, 81209 BLM (Bloom syndrome, RecQ helicase-like) (eg, Bloom syndrome) gene analysis, 2281del6ins7 variant 81242 FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis 81243 FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis 81250 G6PC (glucose-6-phosphatase, catalytic subunit) gene analysis 81251 GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis 81255 HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, 81256 HFE (hemochromatosis) gene analysis, common variants (eg, C282Y, H63D) 81257 HBA1/HBA2 (alpha globin 1 and alpha globin 2, gene analysis 81260 IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) 81280 Long QT syndrome gene analyses, full sequence analysis 81282 Duplication/deletion variants 81290 MCOLN1 (mucolipin 1)(eg, Mucolipidosis, type IV) gene analysis 81302 MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis 81317 PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) gene analysis; full sequence analysis 81318 Known familial variants 81319 Duplication/deletion variants 81330 SMPD1 (sphingomyelin phosphodiesterase 1, acid lysosomal) gene analysis 81331 SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) 81332 SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) gene analysis 81252-81253 GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) gene analysis 81321-81323 PTEN (phosphatase and tensin homolog) gene analysis 81324-81326 PMP22 (peripheral myelin protein 22) gene analysis 88245-88269 Chromosome analysis 88271-88275 Molecular cytogenetics 81420 Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel 81507 Fetal aneuploidy (trisomy 21, 18 and 13) DNA sequence analysis of selected regions using maternal plasma 81200, 81209 ASPA (aspartoacylase)(eg, Canavan disease) gene analysis 81242-81244 81242:FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis 81243:FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis 81244:FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis 81251-81255, 81257 81260, 81290, 81330 81400, 81401, 81403-81405 81251:GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis 81252:GJB2 (gap junction protein, beta 2, 26kDa, connexin 26),gene analysis, full gene sequence 81253:GJB2 (gap junction protein, beta 2, 26kDa, connexin 26), gene analysis; known familial variants 81254:GJB6 (gap junction protein, beta 6, 30kDa, connexin 30), gene analysis 81255:HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis 81257:HBA1/HBA2 (alpha globin 1 and alpha globin 2), gene analysis I81260:KBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) gene analysis 81290:MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis 81330:SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis 81400:Molecular pathology procedure, Level 1 81401:Molecular pathology procedure, Level 2 81403:Molecular pathology procedure, Level 4 81404:Molecular pathology procedure, Level 5 81405:Molecular pathology procedure, Level 6 Pre-implantation Genetic Testing Prenatal Screening S3844 - S3846 S3844: DNA analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness S3845: Genetic testing for alpha-thalassemia S3846: Genetic testing for hemoglobin e beta-thalassemia S3849, S38450 S3849: Genetic testing for niemann-pick disease S3850: Genetic testing for sickle cell anemia